Difference between revisions of "Cytarabine liposomal (DepoCyt)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[ | + | Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021041s031lbl.pdf Cytarabine liposomal (DepoCyt) package insert]</ref><ref>[[Media:Cytarabineliposomal.pdf | Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)]]</ref><ref>[http://depocyt.com/ Depocyt manufacturer's website]</ref> |
<br>Route: IT | <br>Route: IT | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| Line 13: | Line 13: | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021041s031lbl.pdf Cytarabine liposomal (DepoCyt) package insert]<ref name="insert"></ref> | ||
*[http://chemocare.com/chemotherapy/drug-info/cytarabine-liposomal.aspx Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cytarabine-liposomal.aspx Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/cytarabine-liposomal.aspx Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cytarabine-liposomal.aspx Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/liposomal-cytarabine-patient-drug-information Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)]</ref> | ||
Revision as of 10:38, 4 April 2021
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2][3]
Route: IT
Extravasation: irritant
- "In-line filters must not be used when administering DepoCyt."[1]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cytarabine liposomal (DepoCyt) package insert[1]
- Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)[4]
- Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 4/1/1999: Initial FDA approval
- 8/11/2011: (earliest label available on Drugs@FDA) indicated for the intrathecal treatment of lymphomatous meningitis.
Also known as
- Generic name: Liposomal Ara-C
- Brand name: DepoCyt
References
- ↑ 1.0 1.1 1.2 1.3 Cytarabine liposomal (DepoCyt) package insert
- ↑ Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)
- ↑ Depocyt manufacturer's website
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)